Recent Articles
Spooky Halloween and Diwali Blessings!
AT A GLANCE After a whole night of spooky fun and plenty of treats, may this Diwali bring peace and prosperity to your life! Wishing you and...
Read More
Novo Asks FDA to Restrict Compounded GLP-1 Meds; The Economist’s Ozempic Edition; GLP-1 May Drive
AT A GLANCE Novo Nordisk wants to prevent compounding pharmacies from making its GLP-1 meds, as they are too complex for manufacturers to make safely,...
Read More
FDA Reverses Position on Tirzetapide Shortages; UK NHS Tackles Obesity; Telehealth GLP-1 Gold Rush; Superior
AT A GLANCE Endpoints News leads with the surprising twist, that the FDA said it would rethink ending the shortage of Eli Lilly’s weight loss drug tirzepatide....
Read More
FDA Sued on Removal of Tirzetapide from Shortage List; Eli Lilly Sends Cease-and-Desist Letters; Could
AT A GLANCE STAT reports The Outsourcing Facilities Association, has sued the FDA for a ‘reckless and arbitrary’ decision to remove tirzetapide from the shortages list. Eli Lilly...
Read More
Roche, Metsera and Kailera Advance on Obesity Drug Development; Tirzetapide Shortage is Over, per FDA;
AT A GLANCE From STAT, Chief Executive of Roche’s pharma division, Teresa Graham, says on weight loss drugs ‘… that in a $100- to $250-billion market, there’s a...
Read More
Metsera’s Long-Acting GLP-1; Mount Sinai Partners with Noom; Wegovy and Medicare Price Negotiations; New Guidelines
AT A GLANCE STAT’s Elaine Chen on Novo Nordisk’s trial of cannabinoid CB1 receptor inhibitor monlunabant, with modest 6.4% weight loss and some psychiatric side effects. Metsera announced phase...
Read More